3-{[3-(trifluoromethyl)phenyl]amino}but-2-enenitrile | 327105-39-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-{[3-(trifluoromethyl)phenyl]amino}but-2-enenitrile
• 英文别名: 3-{[3-(trifluoromethyl)phenyl]amino}-2-butenenitrile；3-[3-(trifluoromethyl)anilino]but-2-enenitrile
• CAS: 327105-39-5
• 化学式: C₁₁H₉F₃N₂
• 分子量: 226.201
• InChiKey: MKNVYQSYRYDZIW-UHFFFAOYSA-N

物化性质

• 沸点：
  283.5±40.0 °C(Predicted)
• 密度：
  1.265±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  35.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-{[3-(trifluoromethyl)phenyl]amino}but-2-enenitrile 、 dimethyl 2-(4-cyanobenzylidene)malonate 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 叔丁醇 为溶剂， 以32%的产率得到4-(4-cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridine-3-carbonitrile
  参考文献：
  名称：

  冻结生物活性构象以增强效能：BAY 85-8501的鉴定，BAY 85-8501是人类中性粒细胞弹性蛋白酶对肺部疾病的选择性和强效抑制剂

  摘要：

  Human neutrophil elastase (HNE) is a key protease for matrix degradation. High HNE activity is observed in inflammatory diseases. Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH). HNE inhibitors

  DOI：

  10.1002/cmdc.201500131
• 作为产物：
  描述：

  3-氨基巴豆腈 、 间氨基三氟甲苯 在 溶剂黄146 作用下， 以 水 为溶剂， 反应 0.5h， 以23%的产率得到3-{[3-(trifluoromethyl)phenyl]amino}but-2-enenitrile
  参考文献：
  名称：

  冻结生物活性构象以增强效能：BAY 85-8501的鉴定，BAY 85-8501是人类中性粒细胞弹性蛋白酶对肺部疾病的选择性和强效抑制剂

  摘要：

  Human neutrophil elastase (HNE) is a key protease for matrix degradation. High HNE activity is observed in inflammatory diseases. Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH). HNE inhibitors

  DOI：

  10.1002/cmdc.201500131

文献信息

• Dihydropyridinone derivatives
  申请人：Gielen-Haertwig Heike

  公开号：US20060100207A1

  公开（公告）日：2006-05-11

  The invention relates to novel dihydropyridinone derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

  本发明涉及新型二氢吡啶酮衍生物，其制备方法以及它们在药物中的应用，特别是用于治疗慢性阻塞性肺疾病、急性冠状动脉综合征、急性心肌梗死和心力衰竭的发展。
• Dihydropyridine derivatives for use as human neutrophil elastase inhibitors
  申请人：Gielen-Haertwig Heike

  公开号：US20070167406A1

  公开（公告）日：2007-07-19

  The invention relates to novel dihydropyridine derivatives, of Formula (I) processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

  本发明涉及一种新型二氢吡啶衍生物，其化学式为(I)，以及其制备方法和在药物中的应用，尤其是用于治疗慢性阻塞性肺疾病、急性冠状动脉综合症、急性心肌梗死和心力衰竭的发展。
• [EN] DIHYDROPYRIDINONE DERIVATIVES AS HNE INHIBITORS<br/>[FR] DERIVES DE DIHYDROPYRIDINONE
  申请人：BAYER HEALTHCARE AG

  公开号：WO2004020410A3

  公开（公告）日：2004-04-22
• Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases
  作者：Franz von Nussbaum、Volkhart M.-J. Li、Swen Allerheiligen、Sonja Anlauf、Lars Bärfacker、Martin Bechem、Martina Delbeck、Mary F. Fitzgerald、Michael Gerisch、Heike Gielen-Haertwig、Helmut Haning、Dagmar Karthaus、Dieter Lang、Klemens Lustig、Daniel Meibom、Joachim Mittendorf、Ulrich Rosentreter、Martina Schäfer、Stefan Schäfer、Jens Schamberger、Leila A. Telan、Adrian Tersteegen

  DOI：10.1002/cmdc.201500131

  日期：2015.7

  Human neutrophil elastase (HNE) is a key protease for matrix degradation. High HNE activity is observed in inflammatory diseases. Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH). HNE inhibitors

  Human neutrophil elastase (HNE) is a key protease for matrix degradation. High HNE activity is observed in inflammatory diseases. Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH). HNE inhibitors